14 completed, 5 unknown, 3 recruiting, 1 active not recruiting. 24 Phase 2, 6 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 14, Unknown 5, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 6 | Unknown 4, Completed 2 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder | Phase 2 | Recruiting | Amit Lotan | 80 | 2026-08-12 | 2026-09-29 |
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease | Phase 2 | Recruiting | Inova Health Care Services | 100 | 2025-10-07 | 2026-09-09 |
| Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients Deferiprone Tablets, Placebo - Acute Myocardial Infarction Type 1 | Phase 2 | Recruiting | Rohan Dharmakumar | 89 | 2022-11-08 | 2026-09-29 |
| Ferritin and Iron Burden in SAH sIRB Deferiprone pill, placebo, Montreal Cognitive Assessment - SAH, Dementia | Phase 1 / Phase 2 | Active not recruiting | Duke University | 66 | 2020-10-01 | 2026-07-20 |
| Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage) - Iron Overload Due to Repeated Red Blood Cell Transfusions | Phase 2 | Completed | ApoPharma | 30 | 2019-03-06 | 2021-07-16 |
| Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 372 | 2019-01-30 | 2025-12-05 |
| Deferiprone to Delay Dementia (The 3D Study) Deferiprone 600mg delayed release tablets, Placebo Oral Tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2 | Completed | Neuroscience Trials Australia | 81 | 2018-01-19 | 2024-07-03 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| Study of Parkinson's Early Stage With Deferiprone Deferiprone, Placebo - Parkinson's Disease | Phase 2 | Completed | ApoPharma | 140 | 2016-10-12 | 2024-04-10 |
| Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease Deferiprone, Placebo - Parkinson Disease | Phase 2 | Completed | University Hospital, Lille | 372 | 2016-02-09 | 2026-02-05 |
| Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients Deferiprone - Myelodysplastic Syndrome With Low-grade Lesions, Iron Overload Due to Repeated Red Blood Cell Transfusions | Phase 2 | Completed | Sheba Medical Center | 19 | 2016-02-01 | 2018-11-01 |
| An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Deferiprone - Beta Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2014-07-01 | 2015-01-14 |
| Role of Vitamin C to Augment Iron Chelation With DFP or DFX Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2014-04-01 | 2014-03-11 |
| Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Deferiprone - ALS (Amyotrophic Lateral Sclerosis), Iron Overload | Phase 2 | Completed | University Hospital, Lille | 23 | 2013-09-01 | 2026-02-20 |
| Pharmacokinetic Study of Deferiprone in Paediatric Patients Deferiprone, dose level 1, Deferiprone, dose level 2, Deferiprone, dose level 3 - Chronic Iron Overload | Phase 2 | Completed | Consorzio per Valutazioni Biologiche e Farmacologiche | 23 | 2012-12-01 | 2017-01-11 |
| Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia Deferasirox and deferiprone - Thalassemia Major With Severe Transfusional Iron Overload | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 9 | 2012-09-01 | 2019-03-06 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2012-02-01 | 2012-02-06 |
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease Deferiprone 20mg, Placebo, Deferiprone 30mg - Parkinson's Disease | Phase 2 | Completed | Imperial College London | 22 | 2012-02-01 | 2020-06-16 |
| Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease deferiprone, placebo - Parkinson's Disease | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 40 | 2009-10-01 | 2026-05-14 |
| A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Deferiprone oral solution 100mg/mL, Deferiprone oral solution 100 mg/mL - Friedreich's Ataxia | Phase 2 | Completed | ApoPharma | 36 | 2009-06-01 | 2011-06-27 |
Showing 20 of 24. Sign in to see all of them.
Iron Overload (5) · beta-Thalassemia (5) · Parkinson Disease (4) · Amyotrophic Lateral Sclerosis (2) · Anemia, Sickle Cell (2) · Dementia (2) · Friedreich Ataxia (2) · Thalassemia (2) · Alzheimer Disease (1) · Arrhythmias, Cardiac (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Diabetes Mellitus (1) · Hearing Loss, Sensorineural (1)
ApoPharma (4) · University Hospital, Lille (4) · Ain Shams University (3) · Amit Lotan (1) · Carelon Research (1) · Children's Hospital of Philadelphia (1) · Consorzio per Valutazioni Biologiche e Farmacologiche (1) · Duke University (1) · Ente Ospedaliero Ospedali Galliera (1) · Hadassah Medical Organization (1) · Imperial College London (1) · Inova Health Care Services (1) · Lipomed (1) · Neuroscience Trials Australia (1) · Rohan Dharmakumar (1)
France (7) · United States (6) · Italy (5) · Egypt (4) · Canada (3) · Israel (3) · Spain (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Germany (2) · Austria (1) · Cyprus (1) · Czechia (1) · Greece (1)
Arnold Munnich, M.D. (2) · David Devos, MD, PhD (2) · Massimo Pandolfo, M.D. (2) · Ashley I. Bush (1) · Caroline Moreau, MD (1) · David Devos, MD (1) · David Devos, MD,PhD (1) · David Hasan, MD (1) · David T Dexter, PhD (1) · David Zangen, Professor (1) · Drorit Merkel, MD (1) · Elliott P, Vichinsky, MD (1) · Ellis J. Neufeld, MD (1) · Franco Taroni (1) · Franco Taroni, M.D. (1)
PMID 37975597, PMID 11054091, PMID 16540422, PMID 17976187, PMID 18704280, PMID 20938663, PMID 21599434, PMID 21791473, PMID 2265118, PMID 23937987, PMID 24251381, PMID 25600572, PMID 25943368, PMID 28469157, PMID 29119631, PMID 29287521, PMID 29380903, PMID 32726602, PMID 33236783, PMID 36449420, PMID 37975798, PMID 39495531, PMID 39952690, PMID 39973479, PMID 8047081, PMID 8619408, PMID 8959943, PMID 9633879
2008 (1), 2015 (1), 2017 (1), R01HL133407 (1), U01HL065232 (1), U01HL065238 (1), U01HL065239 (1), U01HL065244 (1), U01HL065260 (1)